



ELSEVIER

Contents lists available at ScienceDirect

## Journal of Experimental and Clinical Medicine

journal homepage: <http://www.jecm-online.com>Journal of  
Experimental  
and  
Clinical  
Medicine

## Keyword Index

<b>A</b>		<b>D</b>	
activin A	6:222	demographic factors	6:102
adverse drug event	6:139	dental implant	6:203
analgesia	6:83	depot antipsychotic drug	6:200
antibiotic resistance	6:16	diindolylmethane	6:132
antimicrobial stewardship	6:143	DNA methylation	6:75
antinociception(analgesia)	6:151	drug-resistant bacteria	6:143
anxiety disorders	6:179	dynorphin A <sub>1-17</sub>	6:151
articular cartilage defect	6:118		
asthma	6:102	<b>E</b>	
attention-deficit/hyperactivity disorder	6:179, 190	electrical field stimulation	6:98
atypical antipsychotic drug	6:111	endoscopy	6:209
autism spectrum disorder	6:179	epidemiology	6:1
autoimmune disease	6:57	epidural anesthesia	6:83
		epigenetics	6:75
		erlotinib	6:98
		erythroid genes	6:222
		<i>Escherichia coli</i>	6:187
		evidence-based practice	6:157
<b>B</b>			
bacterial infection	6:94	<b>F</b>	
benefit:cost ratio	6:139	fentanyl	6:83
biomechanics	6:203	finite-element method	6:203
bioreactor	6:10		
bipolar disorder	6:111	<b>G</b>	
bladder cancer	6:132	gefitinib therapy	6:50
bone regeneration	6:10	genetic polymorphism	6:195
breast	6:161	gold nanoparticles	6:172
bupivacaine	6:83	Group B <i>Streptococcus</i>	6:187
<b>C</b>			
c-Jun	6:222	<b>H</b>	
cancer	6:1	haloperidol	6:200
<i>Candida</i> infection	6:90	health service utilization	6:125
cephalexin	6:94	histone modifications	6:75
chemoprevention	6:132	hospital-acquired pneumonia	6:157
children and adolescents	6:179	human serum bactericidal activity	6:16
cholinergic effect	6:98	hyperalgesia	6:151
chronic inflammatory demyelinating polyneuropathy	6:43		
clinical predictor	6:43	<b>I</b>	
colistin	6:213	immunotherapy	6:43
communication difficulty	6:217	infant bacteremia	6:187
compulsive Internet use	6:190	infant mortality	6:125
critically ill patient	6:209	infants	6:1
cytokines	6:50		
cytomegalovirus colitis	6:209		

infection control	6:157	pharmacist intervention	6:139, 143
interleukin-21	6:57	phyllodes tumor	6:161
interleukin-21 receptor	6:57	platelet-rich plasma	6:118
<b>K</b>		pneumonia	6:213
K562 cells	6:222	pulmonary function	6:102
<b>L</b>		<b>Q</b>	
length of hospitalization	6:90	quality of life	6:102, 125, 217
leukemia	6:1	<b>R</b>	
<b>M</b>		recurrence	6:161
medication adherence	6:200	red blood cell hemagglutination	6:16
medication management and use	6:139	referral	6:217
mesenchymal stems cells	6:10	reticuloendothelial system	6:172
Met-enkephalin	6:151	rheumatoid arthritis	6:57
metabolic syndrome	6:195	risperidone	6:111, 200
mitochondrial activity	6:21	<b>S</b>	
mood disorders	6:179	schizophrenia	6:111
mortality	6:90	socioeconomic factors	6:125
<b>N</b>		solid tumors	6:1
<i>N</i> -butyl- <i>N</i> -(4-hydroxybutyl)		<i>Staphylococcus aureus</i>	6:187
nitrosamine	6:132	stress	6:203
nanomedicine	6:172	swallowing difficulty	6:217
nasal packings	6:94	symptom cluster	6:50
nerve excitability	6:43	synovial mesenchymal stem cells	6:118
non-small-cell lung cancer	6:50	<b>T</b>	
noncoding RNAs	6:75	thermosensitive hydrogel	6:118
nosocomial infection	6:90, 143, 157, 213	three-dimensional dynamic culture	6:10
<b>O</b>		tigecycline	6:213
OSC2 cells	6:21	titanates	6:21
<b>P</b>		TNF- $\alpha$	6:222
peroxisome proliferator-activated		topical antibiotics	6:94
receptor gamma	6:195	tracheal smooth muscle	6:98
pervasive developmental disorder	6:179	<b>W</b>	
		wide excision	6:161